univers coverag
calendar event
medacorp puls call anti-trust outlook vertic mega-merg pbms/
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
regulatori event presid trump speech drug price link preview note fda
joint adcom pediatr endocrinolog metabol drug vosoritid asnd
medic meet european wound manag associ european societi
pediatr gastroenterolog hepatolog nutrit heart rhythm societi societi
bottom line provid addit medacorp specialist insight ahead presid
trump speech today pm drug price reform highlight white hous
call last night focus quicker gener biosimilar market line previou call
fda agenda scott gottlieb lower list price focu reduc freeload
countri lower out-of-pocket cost senior like po discount also spoke
medacorp pbm industri specialist believ chang take time implement
given plan design often least month less price dispers across custom
price converg close around mean improv specialti could
outcomes-bas price vertic integr pbm well posit continu view
headlin risk impact part remain manag given plan make small
oper profit annual mid-singl digit margin expect rebat
reduct share consum pass medicar program off-set save
elsewher chang part perspect pbm
impact op optum rx ci op esrx mp deal op
aet mp initi date alreadi contempl drug rebat share consum point
sale po discount employ sponsor insur aet drug rebat
pass employ entiti valu chain
white hous held brief call tonight provid high level overview trump america patient
quicker gener biosimilar market line previou call fda agenda
lower list price drug littl mechan provid tonight call
lower out-of-pocket cost senior littl detail provid perhap po discount
pbm pass major rebat
spoke medacorp pbm industri specialist believ idea outlin trump speech
may take time implement given current benefit design set month
flexibl formulari
specialist believ rebat go away integr pbm come togeth less price
dispers custom type price converg around mean
specialist believ focu outcomes-bas price integr pbm
optum rx ci esrx aet well posit
pbm innov
white hous call also provid goal decreas foreign govern freeload littl detail
driver achiev
previou drug price speech preview call avail follow link
asco titl highlight i/o progress emerg novel tki
bottom line note review titl upcom american societi clinic
oncolog meet june highlight chang io landscap focu
develop lung cancer prospect io combin light failur mrk/inci
trial emerg data new checkpoint beyond axi extend follow
data first gener car-t updat blue/celg bcma program adap
tcr pipelin final addit present believ garner investor interest
note contain vari level concentr import abstract highest
impact abstract titl complet univers abstract find
interest biopharmaceut coverag complet list select titl found
recap auph strong start fund pipelin
bottom line market close auph releas financi result report
cash cash equival compani believ provid runway
furthermor management state clinic pipelin remain track wit start
trial focal segment glomerular sclerosi fsg well program dri
eye syndrom de capit uniqu immunomodul properti
lead asset voclosporin even though model either program due earli stage clinic
develop eager see program unfold remaind year meanwhil
enrol compani pivot aurora trial -- evalu voclosporin lupu nephriti
ln -- progress swiftli recruit complet anticip readout top-line
result guid compani plan submit first modul roll nda
ln program recent discuss detail link optimist likelihood
success ln po look forward expans renal franchis fsg well
compani suit indic de updat model reflect auph
pivot aurora studi posit auph first-to-market ln indic
expans auph renal franchis fsg set occur june initi studi
initi head-to-head toler studi voclosporin ophthalm solut vo vs restasi
cyclosporin ophthalm emuls june posit auph potenti player de
adjust model
revenu mm ep quarterli figur may sum annual total due chang share
recap pipelin track updat
bottom line updat model reflect financi result also provid
pipelin updat in-lin expect includ initi phase ii cantata studi
evalu glutaminas inhibitor combin cabozantinib vs cabozantinib alon renal
cell carcinoma rcc sever updat expect includ plu capecitabin
combin phase ib investigator-sponsor studi data colorect cancer expect
american societi clinic oncolog initi plu paclitaxel phase ii tripl neg
breast cancer tnbc data expect possibl plu opdivo phase i/ii updat data
continu limit visibl time next arginas inhibitor
updat multipl on-going phase combin studi on-going end
cash equival suffici fund oper continu
see well-posit execut long-term strategi strong manag team
revenu million
bottom line cmta releas financi report cash cash
equival anticip provid runway furthermor management state
rare bone diseas program remain track near-term catalyst
horizon lead program fibrodysplasia ossifican progressiva fop
compani intend report month data open-label extens studi
part evalu efficaci lead asset palovaroten reduc new bone volum
fop pt enthusiast readout arm trial provid direct
read on-going pivot move trial continu plan enrol
complet anticip addit compani enter clinic
program evalu palovaroten much larger indic multipl osteochondroma mo
preval fop updat model reflect financi
reiter op pt
near-term fop focu contain catalyt data read-out studi evalu
palovaroten fop
long-term fop focu cmta current conduct world first global trial fop
anticip complet enrol readout
long-term mo focu mo-p studi initi could potenti support
registr indic
revenu ep conform ifr standard
expect
outperform market cap price price target methodolog dcf
cash flow use wacc
bottom line heron report earn today revenu line con
lp ep con lp estim sustol
came roughli line estim con cinvanti notabl better
con lp estim product look rapidli gain share iv
varubi essenti market manag re-affirmed guidanc chemo induc
nausea vomit cinv franchis sustol cinvanti combin sale
reiter op rate pt believ stock fulli reflect peak
potenti given potenti best-in class profil non-opioid altern post-
oper pain manag estim well cinv franchis
estim look addit phase readout
post-op pain phase studi total knee arthroplasti instil breast
augment instil nerv block come day also watch
agenda product consid j-code exparel make list
provid posit read-through well current expect estim
chang model
addit updat press releas
busi remain challeng deal need proven
bottom line follow earn continu remain cautiou stock
new report segment somewhat obscur domest busi result manag
describ distribut busi continu face price margin pressur
conjunct higher cost domest intern distribut
busi led higher cost expect off-set good gross margin quarter
issuanc guidanc delay due complex carve-out halyard
expect given call halyard byram appear progress
well manag sound excit opportun present two busi help
shift higher margin higher growth busi area ep estim stand
price competit pressur continu acut care distribut result higher cost
halyard perform well provid growth margin improv opportun
byram well posit continu shift altern site care
guidanc withheld guidanc issu call
adenosin io valid track tripl look like pt
dcf valuat use discount rate lt growth rate
bottom line arcu bioscienc report financi result yesterday
afternoon provid updat plan first-in-pati trial lead candid
potent dual antagonist previous plan basket trial split three
independ platform trial test combin antibodi
standard-of-car chemotherapi welcom chang trial structur allow
flexibl futur addit extra arm explor tripl combin chemotherapi
checkpoint antibodi in-hous antibodi hand well posit contempl
potenti collabor biopharma player expedit develop tripl
combin even ultim dont includ result
tripl combin disclos investor expect confirm activ
phase dose escal studi underway complet
follow dose escal phase platform trial efficaci
readout next year anticip readout platform trial major de-risk event
next month believ lead prospect demonstr
potenti benefit target adenosin pathway cancer reiter outperform rate
rais price target primarili base minor account chang model
small tymlo guid yr end share timelin intact pt
 methodolog base dcf thru discount rate termin
bottom line morn radiu report oper result oper loss
ep tymlo sale beat consensu
estim radiu report tymlo averag anabol osteoporosi market
share releas new guidanc expect averag market share captur
analyst seem frustrat spoon-f formal revenu guidanc year simpl
extrapol result potenti total quarterli market size suggest
radiu offer implicit initi full year revenu guid compar consensu
estim believ element guidanc analysi like
conserv given like sequenti market growth lower gross-to-net effect futur
quarter top end guidanc assum sequenti percentag point gain market share
next quarter end year market share tymlo believ hurdl
highli achiev although still depend effect commerci execut payer manag
upsid radiu stock depend potenti elacestr tymlo patch
next catalyst program initi pivot trial year elacestr
next year patch continu believ current stock price discount almost exclus
current inject tymlo revenu profit potenti us reiter outperform rate
increas price target
tymlo sale consensu
timelin intact tymlo label expans patch elacestr phase pivot
model updat expens trend pt
ep exclud stock option expens amort intang
ph iib dose complet set stage hot summer pt
bottom line yesterday market close issu press releas financi
result disclos net loss ep earlier week report
on-going phase iib studi respiratori tract infect rti complet dose
last patient put trial track top-line data readout year follow
disclosur updat model account result well recent
file slightli increas oper expens forecast remaind revis
price target previous reiter outperform rate ahead phase iib
data later summer
model updat higher sg pt op
takeout confirm thesi reiter pt downgrad mp
 methodolog dcf analysi revenu multipl dr tgr
bottom line morn armo announc enter definit agreement
acquir per share consist price target all-cash
transact repres premium armo close price yesterday assum coverag
armo outperform rate price target earlier year assum coverag ph
pass interim safeti analysi remov overhang downgrad armo market perform
outperform previous deal confirm invest thesi armo view could
read posit emerg immuno-oncolog io stock unclear bidder
emerg given short close date transact expect close end
agreement structur cash tender offer acquir share armo follow second-
step merger remain armo share tender acquir tender
ingenio rx ceo brian griffin leav dplo
bottom line flash note morn announc brian griffin formerli
ceo-ingenio rx pbm join dplo ceo chairman board view
relief given strong bull call excel opportun brian griffin
good dplo op view specul move could direct
competitor scale op op see share sold
sinc view best report mco particularli strong buy opportun pt
remain upsid current trade rang
brian griffin appoint ceo chariman dplo excel addit
bottom line morn diplomat pharmaci announc brian griffin former evp
ceo ingeniorx becom ceo chairman dplo effect june mr griffin
substanti industri experi excel hire view march mr griffin
assum evp ceo role ingeniorx task build organ
op prior effort build ingeniorx mr griffin serv evp presid
commerci specialti busi divis provid applic experi
dplo specialty-focus offer mr griffin profession experi includ
leadership role empir bluecross blueshield express script mp medco dplo point
mr griffin dynam skill-set signific industri experi import factor
hire view dplo found excel ceo help lead transit continu
expans pbm offer follow acquisit ldi np
bottom line updat model follow result stick
op rate price target quarter impress na dental
local intern growth view show even though dso on-lin vendor
creat price pressur continu thrive rais revenu estim
slightli reflect solid top-lin perform particularli dental anim health
tweak cost assumpt leav ep mostli unchang manag re-affirmed adj
ep guidanc see resumpt buyback save restructur
potenti earn boost overal see end-market healthi
compani retain leadership posit price pressur may present on-line
competit believ noth new dental distribut compani retain
share value-ad servic remain op stock price target stand
ep adjust non-recur item
recap pipelin track selinexor nda file dlbcl data
bottom line today report financi result provid pipelin updat in-
line expect recent announc posit phase iib storm top-lin result penta-
refractori multipl myeloma patient link key event regulatori nda file
acceler approv selinexor penta-refractori multipl myeloma sadal top-lin selinexor
data relapsed/refractori diffus larg b-cell lymphoma r/r dlbcl base recent medacorp
kol convers link believ recent announc posit storm result highli refractori
multipl myeloma support potenti acceler approv drug set end
cash equival includ net proce public
offer may reiter op
revenu mm
bottom line morn report result mix adj ep trail
estim revenu exceed estim trail consensu report strong gross
margin expans bp y/i off-set higher expect sg tax rate
interest expens acquisit halyard health surgic infect prevent ip
busi close compani issu guidanc may weigh share
view unless guidanc provid call gross margin improv substanti
quarter appear margin pressur continu distribut busi concern
competit price issu firm domest busi kept us mp-rate
share time host confer call estimate look
addit commentari price competit dynam clarifi detail good gross
margin listen manag expect
b/ overhang remov us implant approv hand pt
dcf use wacc long-term growth rate
bottom line deliv solid record-high revenue y/i report
y/i pro-forma basi sale come slightli level pre-announc
bullish stanc remain unchang recent resumpt coverag link come
hot compani fda approv opu implant compani get back offens
us breast implant market -- segment player high
barrier entri financ place believ enough cash bridg cash
flow break-even compani back offens us breast implant believ key
ingredi place signific growth re-acceler trajectori higher share price
market increasingli begin appreci opportun growth
revenu ep
recap final respons fda question follow clinic hold
dcf discount rate termin growth rate
bottom line put clinic hold march link minor updat
clinic hold statu chang sinc compani earn announc
april link timelin sldb lead gene therapi program duchenn muscular
dystrophy/dmd remain tbd becom critic resolv time manner
sarepta op advanc full forc gene therapi program link end
quarter cash cash equival ep loss per share
updat model reflect financi result rais probabl
success po use pre- post- clinic hold lift valuat
blend rais pt remain unchang po reiter
bottom line deliv rev/ebitda expect perhap importantli
two item believ overhang stock saw posit develop
us lower extrem growth acceler track reach hsd market rate exit
shore b/ insur settlement cash inflow
addit capac exist loan agreement compani longer need rais
addt capit continu believ end-market remain healthi grow per management
estim well posit take share within drive hsd sell day
adj growth acceler potenti low-teen view continu
share rebound depress level conting upon steadili improv lower extrem revenue
growth move recent hire lower extrem rep come product curv new
lower extrem prod launch pick steam greater clariti improv b/
cash rais next month longer necessari reiter op pt goe
vs due higher cash/ev assumpt base slightli higher sale
rev/ep continu oper ex-larg joint move disc op ep ex-amort item
testifi commerc committe keep full court press
ev ebitda multipl ebitda less nci
recap higher dose may hit sweet pt
 methodolog dcf analysi discount rate termin growth rate
avatrombopag approv pend label expans effort proceed
dcf discount rate termin valu
solid result continu win
get readi action-pack half reit outperform pt
start year high note
cash flow use wacc termin growth rate
focu remain product catalyst
of-the-part weight average ev/ebitda multipl
ep in-lin top-lin miss off-set lower spend
test volum growth remain intact guid still conserv
compani track updat valuat methodolog pt
dcf analysi discount rate termin growth rate
recap still limbo rest pipelin advanc
analysi discount rate termin growth rate
strong consum growth pharma servic emerg
sale dcf
recap set improv investor confid kidney
outperform market cap price price target methodolog dcf
discount rate termin gr rate
recap await approv lt still hing execut
momentum like wane sever month data
nda/maa come data time valv issu pt
may dova pdufa avathombopag thrombocytopenia chronic liver
fda accept avatrombopag nda prioriti review treatment
thrombocytopenia patient chronic liver diseas cld schedul undergo
presum regul valid dova high degre confid
approv applic basi trial well studi
conduct indic
compani plan immedi launch june approv begun hire
key sale staff includ head us sale deep experi liver diseas drug
dova also remain track complet regulatori submiss ema approv
indic
addit cld indic dova explor label expans opportun broader
pre-surgeri popul thrombocytopenia patient chemotherapy-induc
dova believ opportun tripl size avatrombopag address market
may pdufa peg-pal pegvalias phenylketonuria pku
management remain optimist posit outcom fda convey
peg-pal pku shown lower blood phenylalanin amino acid accumul
pt phase studi
think neurocognit data requir fda registr base
discuss agenc
initi induction/titr phase like translat lower revenu per patient
management note meaning reduct phe consequ well ast
adult pt popul could lead attract market opportun almost sale
price releas upon approv management guid modest premium
ahead may pdufa management appear cautiou potenti launch
highlight lower dose use initi lower revenu per pt pegvalias
revenu may limit downsid impact revenu guidanc
yet pku clinic alreadi experienc pegvalias via clinic trial initi
physician pt feedback presum could help investor better project pku
june american societi clinic oncolog
year meet updat patient treat combin
lead candid mirvetuximab soravtansin avastin
result includ data dose-expans cohort -- patient
avastin-na previous receiv avastin
line treatment set avastin-na pt avastin previous gener
median progression-fre surviv mpf chemotherapi well
earlier present interim clinic data phase ii studi margetuximab
plu mrk keytruda patient advanc line gastric cancer
expand studi enrol addit gastric cancer patient
compani present updat clinic biomark data year june
assign valu probability-weight sale margetuximab
gastroesophag cancer forecast sale
continu await product approv expect
delay believ ttoo long-term outlook depend approv
convers manag suggest fda approv near june time-fram
believ earli demand propos quarter indic
interest
given expect market clearanc expect ttoo add addit
sale rep order penetr hospit rep today ou
manag indic sale forc focus sell total solut rather
candida view appear fundament chang
remain unconvinc ttoo sale execut would like see
approv follow solid sale pickup soon
expect topic jak inhibitor ph ii top-lin data alopecia areata
aa us studi patient one month durat could demonstr
earli valid topic jak inhibitor approach
also develop topic jak janu kinas inhibitor patchi hair loss
possibl androgenet alopecia aga aka male/femal pattern bald
success would open anoth multi-billion dollar market
compani jak inhibitor program treatment immune-medi hair loss
disord aa core upsid driver model account
even use conserv assumpt believ oral jak inhibitor could achiev peak
annual sale aa alon
ph ii top-lin data australia eyebrow studi patient
view agent novel chemic structur avoid format presum toxic
metabolit good reason atogep could avoid liver toxic seen
telcagep follow-on compound
support view gen molecul calcitonin gene-rel peptid cgrp
may avoid liver safeti risk management report un-blind look liver enzym
elev agn on-going atogep studi line placebo event rate
clinic studi
atogep deliv efficaci profil within strike distanc inject
good safeti toler work suggest sizabl market opportun base
inject categori oral late entrant xeljanz rheumatoid arthriti otezla
psoriasi
believ program good chanc success view success
atogep migrain prevent would offer signific valid agn open-sci
next import catalyst alder six month data ph pivot trial
chronic migrain due second quarter
trial expect provid extend durat repeat dose safeti efficaci
month
data expect includ bla eptinezumab need
consist earlier announc data free increas new
advers event increas neutral antibodi
bold ph i/ii x-link myotubular myopathy/xlmtm
audent expect announc updat phase i/ii aspiro data
possibl american societi gene cell therapi confer may
also expect phase i/ii valen data possibl european societi
pediatr gastroenterolog hepatolog nutrit meet may
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
continu optimist ahead pdufa given step taken scph
mitig potenti review risk
manag see signific opportun furoscix reduc patient admiss day
hospit acceler patient discharg reduc readmiss rate
continu believ furoscix subcutan administr gain strong earli
adopt hospital-bas event drive iv furosemid use market
iv diuresi iv furosemid
believ furoscix provid strong pharmacoeconom incent move care
high cost hospit set at-hom set
continu see odd success approv forecast
sale sale
initi furoscix heart failur health econom outcom research studi
june akao pdufa plazomicin gram neg infect
decemb akao report posit top-lin data two phase studi epic
expect support registr expect primari driver
commerci adopt
epic recruit patient suspect complic urinari tract infect cuti
demonstr plazomicin statist non-inferior meropenem fda primari
endpoint statist superior three key efficaci measur includ ema
primari outcom test cure
see nich role plazo treatment-refractori cuti expect drug
primari clinic util carbapenem-resist enterobacteriacea support
compel data studi albeit small sampl show
reduct death/seri complic mortal respect rel
activ control
continu project peak sale plazomicin ww us sale
row royalti us sale come base upon trajectori
agn avycaz accord medacorp kol gener major sale
off-label use infect
compani anticip report ph ii proof-of-concept data
management state observ reduct level -- marker glycem control
dose depend
compani anticip observ dose respons biomark reflect
drug mechan action
goal would posit agent line difficult-to-treat patient use
glycem control compani see potenti market appli
probabl success
model gross sale
believ investor expect head ph ii/iii data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
june present updat analysi pivot
cscc studi focus cemiplimab long-term activ durabl suggest
may addit data studi indic meet
sourc leerink research compani inform factset price prior day
fda joint adcom pediatr endocrinolog metabol drug
presid trump speech drug price link preview note
fda adcom vaccin relat biolog product
hous rep commerc committe opioid legisl mark-up
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
fda adcom joint anesthet analges drug product drug safeti
fda adcom anesthesiolog respiratori therapi devic
pdufa akao plazomicin complic urinari tract infect bloodstream
medcac panel procedur volum requir hospit heart team
member begin maintain transcathet aortic valv replac
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
european societi pediatr gastroenterolog hepatolog nutrit
societi biolog psychiatri
societi pediatr radiolog
abstract releas edt
societi investig dermatolog
american societi gene cell therapi bold
american associ clinic endocrinologist updat afirma
societi neurolog surgeon
world feder hemophilia link
phoenix bardoxolon data renal diseas adpkd lgan link note
european academi allergi clinic immunolog dbvt
american societi clinic psychopharmacolog
american colleg sport medicin
european feder nation associ orthopaed traumatolog
societi imag informat medicin
american societi clinic oncolog adap armo celg
american societi transplant surgeon
american societi neuroradiolog
american societi mass spectrometri
american societi microbiolog
associ profession infect control epidemiolog
uk take-over code may make decis respect
potenti bid shire
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst market
 aducanumab titrat arm bolster evid treatment effect market perform
 ctad medacorp call aducanumab abeta hypothesi
life scienc tool diagnost -- flash fund present posit upsid nih
spend life scienc tool
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt market
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 ttr seri part handicap on-going tafamidi trial fac market
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk group
biopharma -- flash highlight invokana fda warn puls call modest impact
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
biopharma -- flash highlight invokana fda warn puls call modest impact
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
novob dc -- flash near-unanim vote clear path semaglutid approv
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma name shame california latest strategi rein drug price
healthcar distribut suppli chain preview price volum trend appear
hcit distribut outlin possibl drug price polici draconian
fear
 elast demand consist reduc price drive volum growth
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
io clinic trial updat crossroad effici
 deep dive highlight oncolog focu strategi nash market perform
achn recap increment advanc patent complement progress
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst outperform
biopharma might deton event look like screen pot match-
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 add cscc respons diseas boost /sni partnership
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
 atop dermat still without ped leerink dupix
derm survey
 hiv survey rapid adopt biktarvi challeng outlook
gsk
 initi
moat vs
 insight april nyc hc servic day convict
medic suppli devic survey direct posit
mute hope new indications/improv execut
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
 initi could adenosin inhibit unlock wave i/o
outperform
 come-back stori make survey support opu market
share assumpt outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
 rubraca posit base survey lower est due payer assist
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leerink leadership seri new product growth acceler stori market
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devices-cardiolog leerink leadership seri target
outlook alpha opportun abound healthcar share
